Your fact-checks will appear here
The topic is about the cognitive benefits of Bacopa monnieri, including its effects on attention and memory, as well as its tolerability and potential side effects.
The so‑called “Sanjay Gupta honey pill regimen” is not a verified medical protocol promoted by Dr. Gupta but a recurring online scam that uses AI‑generated videos and fake endorsements to sell supplem...
There is no credible evidence that Bacopa monnieri (bacopa) combined with Sidr honey—or any honey—can cure or reverse Alzheimer’s disease; clinical trials of bacopa show small, inconsistent cognitive ...
A randomized, double‑blind, placebo‑controlled pilot trial exists for a product named Memo® (a triple combination of royal jelly, Ginkgo biloba and Panax ginseng) and reported a statistically signific...
Human trials support specific, repeatable dosing ranges for the four compounds: Bacopa monnieri shows benefit in the roughly 150–300 mg/day range taken for weeks to months (effects typically emerge af...
The clinical literature contains a small number of trials that have administered Bacopa monnieri to people with Alzheimer’s disease, but none constitute incontrovertible, high‑quality evidence: a 2022...
Bacopa monnieri has been tested in a modest but consistent body of randomized, placebo‑controlled trials that most systematic reviews and a 2013 meta‑analysis conclude show potential cognitive benefit...
A review of the provided reporting finds no peer‑reviewed clinical trials of the branded supplement Neurocept itself cited in these sources, while the most concrete trial evidence mentioned relates to...
Peer‑reviewed evidence for Bacopa monnieri is substantial and consists of randomized controlled trials, systematic reviews and meta‑analyses showing modest, domain‑specific cognitive benefits—most con...
has a modest but consistent randomized clinical-trial footprint showing small improvements on some memory and attention tests across multiple placebo‑controlled trials and meta‑analyses . The current ...
Multiple randomized, double-blind, placebo-controlled trials have tested standardized Bacopa monnieri extracts (typically 300 mg/day or 150–320 mg twice daily) and found mixed cognitive results: sever...
Bacopa monnieri has been documented to interact with drugs primarily by inhibiting multiple cytochrome P450 (CYP) enzymes—especially CYP3A4, CYP2C9, CYP2C19 and CYP1A2—which can increase blood levels ...
A small randomized, double‑blind, placebo‑controlled pilot trial of a triple‑ingredient product called Memo® (royal jelly + Ginkgo biloba + Panax ginseng) reported short‑term MMSE gains in patients wi...
Clinical evidence for common sold by products like is mixed but suggests modest, domain-specific cognitive benefits for monnieri and in some populations, with generally mild adverse-event profiles rep...
has accrued several randomized, placebo‑controlled trials reporting cognitive benefits—most commonly improvements in memory retention, verbal recall, or speed of attention—with study durations typical...
Randomized trials of Bacopa monnieri in older adults most commonly test daily extract doses in the 300–600 mg range, with treatment periods clustered at about 12 weeks (three months); some studies hav...
Clinical studies that report positive cognitive or anxiolytic effects most often used characterized, extracts — notably 08, ® and older proprietary preparations such as ®/® — typically dosed at roughl...
The evidence base for (BM) in age‑related cognitive decline is dominated by small, short trials and systematic reviews that signal possible benefits for attention and some memory measures but remain i...
has attracted repeated calls for to test whether it can prevent or treat or , but the published and registered work to date consists mainly of small, heterogeneous randomized trials and a single phase...
as a branded dietary supplement carries a blend of ingredients—, , bacopa, , huperzine‑A, N‑acetyl‑carnitine and others—for which some independent clinical studies exist at the ingredient level, but t...
shows consistent neuroprotective and cognitive-enhancing signals in cell and animal models, and small human studies suggest modest cognitive benefits in some settings, but the evidence is heterogeneou...